# Crinetics Pharmaceuticals

Type: Company (CRNX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/crinetics-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/crinetics-pharmaceuticals

## Timeline

- **2026-07**: Vertex announces $10 billion acquisition of Crinetics — Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed.
- **2026**: NDA Submission — Planned submission of paltusotine New Drug Application to the FDA.
- **2026**: Phase 3 Initiation — Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
- **2025-Q4**: Earnings Call — Management confirms commercial readiness and pipeline acceleration.
- **2025-Q3**: PATHFNDR-2 Success — Completion of Phase 3 trial for paltusotine in acromegaly with positive results.

## Recent coverage (2 stories)

### Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout?
2026-07-31 06:14:04 · Sentiment: Bullish · Impact: 6/10 · Sources: 2

Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market.
Full story: https://getbiobrief.com/story/viking-therapeutics-vertex-crinetics-obesity-acquisition-bio

### Crinetics Signals Commercial Readiness as Lead Candidates Near FDA Submission
2026-02-27 01:34:00 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
Full story: https://getbiobrief.com/story/crinetics-crnx-q4-2025-earnings-pipeline-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.